Single-Arm PharmacoKinetic/PharmacoDynamic and Safety Study of Eryaspase (GRASPA) for Patients With Hypersensitivity to PEG-Asparaginase, Diagnosed With Ph(-) Acute Lymphoblastic Leukemia
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2018
At a glance
- Drugs ERY-ASP (Primary) ; Antineoplastics
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms NOR-GRASPALL 2016
- 20 Feb 2018 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
- 20 Feb 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.
- 11 Sep 2017 According to an ERYtech Pharma media release, first patients were recently enrolled in this study.